Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.
Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Since the inception of their partnership five years ago, ATLATL Scientific and Miltenyi Biotec have worked closely together to leverage their respective expertise and resources.
Vitanova Biomedical is developing a prostate-specific membrane antigen targeted drug, VNBp-1, formulated as a first line treatment for local stage prostate cancer.
The initial contract is for 8 months. Todos has also been granted a priority right to supply the lab with up to 75,000 COVID PCR tests per day in the event the laboratory sees significant additional testing demand.
William ‘Obi’ Greenman, Cerus’ president and chief executive officer explains, “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components. “We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.”
Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos Medical will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore.
Veracyte and MAVIDx agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale – up to 40,000 samples per day performed on the easy-to-use nCounter instrument – through technology that attaches molecular barcodes to individual RNA molecules of the virus.
Ensuring an added level of safety, the new filters can be used with ndd’s revolutionary, and highly portable EasyOne® spirometry range, including the EasyOne Air, EasyOne Pro, and EasyOne Pro LAB.
The new voice-enabled health detection and monitoring app from Sonde Health promises to potentially help employers improve employee safety, meet government mandates, and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.
By using this website you agree to accept Medical Device News Magazine Privacy Policy